The Tay-Sachs Disease Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size for Tay-Sachs disease treatment has seen a robust growth in recent years. The market size is projected to increase from $2.28 billion in 2024 to $2.45 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7.5%.
The Tay-Sachs Disease Treatment Global Market Report 2025 forecasts a strong growth for the market, predicting it to reach $3.25 billion by 2029. The projected compound annual growth rate (CAGR) is 7.3%.
Download Your Free Sample of the 2025 Tay-Sachs Disease Treatment Market Report and Uncover Key Trends Now!The key drivers in the tay-sachs disease treatment market are:
• Rising prevalence of lysosomal storage disorders
• Growing awareness initiatives and expansion of genetic testing services
• Increasing demand for symptomatic treatments and rising prevalence of genetic diseases
• Advancements in gene therapy and cost-effective next-generation sequencing.
The tay-sachs disease treatment market covered in this report is segmented –
1) By Treatment: Medication, Respiratory Care, Physical Therapy
2) By Mode Of Administration: Injectable, Oral, Other Mode Of Administration
3) By End-Users: Hospitals, Homecare, Specialty Clinics
Subsegments:
1) By Medication: Antiepileptic Drugs, Miglustat, Supportive Symptomatic Medications
2) By Respiratory Care: Mechanical Ventilation, Airway Clearance Therapy, Oxygen Therapy
3) By Physical Therapy: Motor Function Exercises, Hydrotherapy, Assistive Mobility Devices
The key trends in the tay-sachs disease treatment market are:
• Advancements in gene therapy are trending in this market.
• Cost-effective next-generation sequencing is a significant emerging trend.
• Automated cloning platforms are increasingly shaping the sector's future.
• The integration of AI, machine learning, and adoption of telemedicine solutions are pivotal trends.
Major players in the tay-sachs disease treatment market are:
• Pfizer Inc.
• Sanofi S.A.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics Inc.
• Ultragenyx Pharmaceutical Inc.
• Amicus Therapeutics Inc.
• Spark Therapeutics Inc.
• Rocket Pharmaceuticals Inc.
• RegenxBio Inc.
• Forge Biologics Inc.
• Passage Bio Inc.
• Protalix BioTherapeutics Inc.
• Orchard Therapeutics plc
• Affinia Therapeutics Inc.
• IntraBio Inc.
• Taysha Gene Therapies Inc.
North America was the largest region in the tay-sachs disease treatment market in 2024